Operating profit EBITDA: dermatarx.com (DRMA)

Dermata Therapeutics (DRMA) is implementing advanced acne treatments utilizing micronized silica. The EBITDA metric visualizes current cash efficiency, with the value holding at 0.00. Growth is supported by the robotization of laboratory drug mixing and a streamlined import of raw materials from freshwater sponges, ensuring the stability of US research.

Profit before payment of interest, taxes and amortization: dermatarx.com (DRMA) for 11/23/2025 - 11/12/2026

Dermata Therapeutics, Inc. (DRMA) - metric breakdowns and financial figures

- stock value and consensus price forecast:

Market Chart Dermata Corp|DRMA - Price Target Chart

- company stock exchange capitalization indicators:

Market Capitalization Dermata Therapeutics|DRMA - Enterprise Value

- book value of equity indicators:

Net Assets per Share Dermata Therapeutics|DRMA - Company Book Value|Capitalization to Book Value Ratio dermatarx.com|DRMA - Company Total Assets

- business debt structure and liquidity details:

- company profitability and valuation multiples indicators:

DRMA - Net Income|Future Net Profit Dermata Therapeutics|DRMA - P/E Multiple|Forward P/E Multiple dermatarx.com|DRMA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Dermata Therapeutics|DRMA - Operating profit before deduction of amortization|Earnings per share for the last four quarters Dermata Therapeutics|DRMA - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months dermatarx.com|DRMA - Earnings growth in current year|Expected net earnings per share growth next year Dermata Therapeutics

Analysis of all company metrics:Dermata Corp

Flagship merchandise of Dermata Therapeutics

This indicator measures net cash flow from operating activities before depreciation and amortization, allowing investors to determine the business's actual ability to generate cash through the EBITDA_Co assessment. For Dermata Therapeutics (DRMA), this metric reflects cost management efficiency, as the absence of proprietary manufacturing plants and the outsourcing of clinical trials minimize capital expenditures, directly impacting the final operating profit.

Competitors of Dermata Therapeutics (DRMA)

Operating income before deduction of amortization Krystal Biotech Corp. (KRYS)|APGE - Profit before payment of interest, taxes and amortization|ARQT - Operating profit EBITDA|VCEL: Operating profit EBITDA|ORKA - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sanara MedTech, Inc.|Operating profit before amortization DBVT (DBV Technologies SA)|Operating profit EBITDA SLSN|journeymedicalcorp.com - Operating profit before amortization|Operating profit EBITDA FBRX (Forte Biosciences)|Empro Group Inc. (EMPG) - Profit before interest, taxes and amortization|SLGL - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization AXIL (AXIL Brands, Inc.)|Medicus Pharma Ltd. (MDCX) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Verrica Pharmaceuticals Inc.|HOTH (Hoth Therapeutics Inc.) - Operating profit EBITDA|Operating profit EBITDA Biofrontera Inc|Operating profit before deduction of amortization VYNE (VYNE Therapeutics)|Company profit before taxes, interest and amortization SNOA|Operating profit EBITDA QNRX (Quoin Pharmaceuticals Ltd.)|Operating profit EBITDA azitrainc.com AZTR|ELAB: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RVNC (Revance Therapeutics Inc.)